Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12176 - 12200 of 12280 in total
Investigational
Investigational
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Matched Description: … XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor …
Investigational
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Investigational
Matched Description: … Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Investigational
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Matched Description: … Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting …
Investigational
Investigational
Investigational
A MET receptor tyrosine kinase inhibitor.
Investigational
Matched Description: … A MET receptor tyrosine kinase inhibitor. …
Investigational
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Matched Description: … TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous …
Matched Categories: … Endothelin A Receptor Antagonists …
Investigational
Experimental
Investigational
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Matched Description: … A P2Y12 inhibitor and platelet aggregation inhibitor. …
Investigational
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
Matched Description: … It is a topically delivered small protein that acts as an anti-inflammatory agent. …
Investigational
Investigational
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Matched Description: … It is also a potential therapy for COVID-19. ... This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding …
Investigational
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Matched Description: … ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment …
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Matched Description: … RAV12 is a solid. ... RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric …
Displaying drugs 12176 - 12200 of 12280 in total